US Financial Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-1,636
Closed -$222K 138
2021
Q1
$222K Buy
1,636
+99
+6% +$14.8K 0.06% 136
2020
Q4
$216K Buy
+1,537
New +$197K 0.07% 121

Other funds holding XBI

US Financial Advisors's XBI Position: Q2 2021 in Review

US Financial Advisors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2021, closing a stake of 1,636 shares — an estimated $222K sold.

US Financial Advisors first reported a position in XBI in Q4 2020 and held it in 2 quarters. The position peaked at $222K in Q1 2021. 663 funds tracked by Wall St. Rank hold XBI as of Q2 2021.

  • US Financial Advisors reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2021 after selling out during the quarter.
  • US Financial Advisors sold 1,636 State Street SPDR S&P Biotech ETF shares in Q2 2021, an estimated $222K.
  • US Financial Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q4 2020 and held it in 2 quarters.
  • US Financial Advisors's State Street SPDR S&P Biotech ETF position peaked at $222K in Q1 2021.
  • 663 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2021.

Based on US Financial Advisors's 13F filing for Q2 2021, filed 10 Aug 2021.